Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 28576867)

  • 1. Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study).
    Garlan F; Laurent-Puig P; Sefrioui D; Siauve N; Didelot A; Sarafan-Vasseur N; Michel P; Perkins G; Mulot C; Blons H; Taieb J; Di Fiore F; Taly V; Zaanan A
    Clin Cancer Res; 2017 Sep; 23(18):5416-5425. PubMed ID: 28576867
    [No Abstract]   [Full Text] [Related]  

  • 2. Association of emergence of new mutations in circulating tumuor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer.
    Jia N; Chang L; Gao X; Shi X; Dou X; Guan M; Shao Y; Li N; Cheng Y; Ying H; Sun Z; Zhou Y; Zhao L; Zhou J; Bai C
    BMC Cancer; 2021 Jul; 21(1):845. PubMed ID: 34294055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Sequencing of Circulating Tumor DNA to Monitor Genetic Variants and Therapeutic Response in Metastatic Colorectal Cancer.
    Hsu HC; Lapke N; Wang CW; Lin PY; You JF; Yeh CY; Tsai WS; Hung HY; Chiang SF; Chen HC; Chen SJ; Hsu A; Yang TS
    Mol Cancer Ther; 2018 Oct; 17(10):2238-2247. PubMed ID: 29997152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer.
    Osumi H; Shinozaki E; Yamaguchi K; Zembutsu H
    Sci Rep; 2019 Nov; 9(1):17358. PubMed ID: 31758080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer.
    Max Ma X; Bendell JC; Hurwitz HI; Ju C; Lee JJ; Lovejoy A; Mancao C; Nicholas A; Price R; Sommer N; Tikoo N; Yao L; Yaung SJ; Palma JF
    Clin Cancer Res; 2020 Aug; 26(15):4010-4017. PubMed ID: 32220893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer.
    Moati E; Blons H; Taly V; Garlan F; Wang-Renault SF; Pietrasz D; Didelot A; Garrigou S; Saint A; Pernot S; Taieb J; Laurent-Puig P; Zaanan A
    Int J Cancer; 2020 Aug; 147(4):1185-1189. PubMed ID: 31472013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer.
    Lyskjær I; Kronborg CS; Rasmussen MH; Sørensen BS; Demuth C; Rosenkilde M; Johansen AFB; Knudsen M; Vang S; Krag SRP; Spindler KG; Andersen CL
    Sci Rep; 2019 Aug; 9(1):11542. PubMed ID: 31395942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial.
    Lueong SS; Herbst A; Liffers ST; Bielefeld N; Horn PA; Tannapfel A; Reinacher-Schick A; Hinke A; Hegewisch-Becker S; Kolligs FT; Siveke JT
    Clin Chem; 2020 Dec; 66(12):1510-1520. PubMed ID: 33257977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Emergent Circulating Tumor DNA
    Kim TW; Peeters M; Thomas A; Gibbs P; Hool K; Zhang J; Ang AL; Bach BA; Price T
    Clin Cancer Res; 2018 Nov; 24(22):5602-5609. PubMed ID: 29898991
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA.
    Wei Q; Zhang Y; Gao J; Li J; Li J; Li Y; Zhou J; Lu M; Gong J; Zhang X; Shen L; Sun Y; Chang L; Wang X
    Clin Colorectal Cancer; 2019 Sep; 18(3):175-182. PubMed ID: 31227437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR.
    Lim Y; Kim S; Kang JK; Kim HP; Jang H; Han H; Kim H; Kim MJ; Lee KH; Ryoo SB; Park JW; Jeong SY; Park KJ; Kang GH; Han SW; Kim TY
    Sci Rep; 2021 Aug; 11(1):16333. PubMed ID: 34381078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A higher ctDNA fraction decreases survival in regorafenib-treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study.
    Unseld M; Belic J; Pierer K; Zhou Q; Moser T; Bauer R; Piringer G; Gerger A; Siebenhüner A; Speicher M; Heitzer E; Prager GW
    Int J Cancer; 2021 Mar; 148(6):1452-1461. PubMed ID: 32949150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
    Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma.
    Bachet JB; Blons H; Hammel P; Hariry IE; Portales F; Mineur L; Metges JP; Mulot C; Bourreau C; Cain J; Cros J; Laurent-Puig P
    Clin Cancer Res; 2020 Oct; 26(19):5208-5216. PubMed ID: 32605910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial.
    Bidard FC; Kiavue N; Ychou M; Cabel L; Stern MH; Madic J; Saliou A; Rampanou A; Decraene C; Bouché O; Rivoire M; Ghiringhelli F; Francois E; Guimbaud R; Mineur L; Khemissa-Akouz F; Mazard T; Moussata D; Proudhon C; Pierga JY; Stanbury T; Thézenas S; Mariani P
    Cells; 2019 May; 8(6):. PubMed ID: 31142037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
    Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
    World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of circulating tumor DNA for colorectal cancer.
    Osumi H; Shinozaki E; Yamaguchi K; Zembutsu H
    Cancer Sci; 2019 Apr; 110(4):1148-1155. PubMed ID: 30742729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation.
    Mo S; Ye L; Wang D; Han L; Zhou S; Wang H; Dai W; Wang Y; Luo W; Wang R; Xu Y; Cai S; Liu R; Wang Z; Cai G
    JAMA Oncol; 2023 Jun; 9(6):770-778. PubMed ID: 37079312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
    Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
    JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer.
    Osumi H; Shinozaki E; Takeda Y; Wakatsuki T; Ichimura T; Saiura A; Yamaguchi K; Takahashi S; Noda T; Zembutsu H
    Cancer Med; 2019 Jan; 8(1):408-417. PubMed ID: 30575318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.